Ethinyl estradiol; levonorgestrel - Generic Drug Details

What are the generic sources for ethinyl estradiol; levonorgestrel and what is the scope of freedom to operate?

Ethinyl estradiol; levonorgestrel is the generic ingredient in fifty-five branded drugs marketed by Agile, Glenmark Pharms Ltd, Avion Pharms, Lupin Ltd, Novast Labs, Aurobindo Pharma Ltd, Xiromed, Naari Pte, Watson Labs, Dr Reddys Labs Sa, Aurobindo Pharma, Teva Branded Pharm, Wyeth Pharms Inc, Sun Pharm, Exeltis Usa Inc, Cadence Health, Duramed Pharms Barr, Barr, Bayer Hlthcare, Wyeth Pharms, Novast Labs Ltd, Amneal Pharms, Hetero Labs, and Ph Health, and is included in seventy-six NDAs. There are six patents protecting this compound and five Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Ethinyl estradiol; levonorgestrel has sixty-seven patent family members in twenty countries.

Twenty-three suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for ethinyl estradiol; levonorgestrel

International Patents:	67
US Patents:	6
Tradenames:	55
Applicants:	24
NDAs:	76
Finished Product Suppliers / Packagers:	23
Clinical Trials:	74
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ethinyl estradiol; levonorgestrel
DailyMed Link:	ethinyl estradiol; levonorgestrel at DailyMed

Recent Clinical Trials for ethinyl estradiol; levonorgestrel

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
HIV Prevention Trials Network	PHASE2
National Institute of Allergy and Infectious Diseases (NIAID)	PHASE2
Atea Pharmaceuticals, Inc.	PHASE1

See all ethinyl estradiol; levonorgestrel clinical trials

Generic filers with tentative approvals for ETHINYL ESTRADIOL; LEVONORGESTREL

Applicant	Application No.	Strength	Dosage Form
		0.03MG,0.01MG; 0.15MG,N/A	TABLET;ORAL
		0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for ethinyl estradiol; levonorgestrel

Drug Class	Estrogen Progestin Progestin-containing Intrauterine System
Mechanism of Action	Estrogen Receptor Agonists
Physiological Effect	Inhibit Ovum Fertilization

Anatomical Therapeutic Chemical (ATC) Classes for ethinyl estradiol; levonorgestrel

G03AC	Progestogens
G03A	HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

G03AD	Emergency contraceptives
G03A	HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

G03CA	Natural and semisynthetic estrogens, plain
G03C	ESTROGENS
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

Paragraph IV (Patent) Challenges for ETHINYL ESTRADIOL; LEVONORGESTREL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BALCOLTRA	Tablets	ethinyl estradiol; levonorgestrel	0.1 mg/0.02 mg	208612	1	2020-07-14
QUARTETTE	Tablets	ethinyl estradiol; levonorgestrel	0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg and 0.01 mg	204061	1	2013-07-10
LOSEASONIQUE	Tablets	ethinyl estradiol; levonorgestrel	0.1 mg/0.02 mg and 0.01 mg	022262	1	2009-11-16
SEASONIQUE	Tablets	ethinyl estradiol; levonorgestrel	0.15 mg/0.03 mg/0.01 mg	021840	1	2008-01-22
LYBREL	Tablets	ethinyl estradiol; levonorgestrel	0.09 mg/0.02 mg	021864	1	2007-10-05
SEASONALE	Tablets	ethinyl estradiol; levonorgestrel	0.15 mg/0.03 mg	021544	1	2004-03-29

US Patents and Regulatory Information for ethinyl estradiol; levonorgestrel

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	LEVLITE	ethinyl estradiol; levonorgestrel	TABLET;ORAL-21	020860-001	Jul 13, 1998		DISCN	Yes	No
Amneal Pharms	LEVONORGESTREL AND ETHINYL ESTRADIOL	ethinyl estradiol; levonorgestrel	TABLET;ORAL-28	201095-001	Dec 8, 2014		DISCN	No	No
Glenmark Pharms Ltd	LEVONORGESTREL AND ETHINYL ESTRADIOL	ethinyl estradiol; levonorgestrel	TABLET;ORAL	202791-001	Apr 9, 2015	AB	RX	No	No
Xiromed	LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL	ethinyl estradiol; levonorgestrel	TABLET;ORAL	206053-001	Oct 2, 2017	AB	RX	No	No
Xiromed	LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL	ethinyl estradiol; levonorgestrel	TABLET;ORAL	200493-001	Jun 17, 2015	AB	RX	No	No
Barr	LEVONORGESTREL AND ETHINYL ESTRADIOL	ethinyl estradiol; levonorgestrel	TABLET;ORAL-28	075862-002	Apr 29, 2003		DISCN	No	No

Expired US Patents for ethinyl estradiol; levonorgestrel

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Branded Pharm	SEASONIQUE	ethinyl estradiol; levonorgestrel	TABLET;ORAL	021840-001	May 25, 2006
Teva Branded Pharm	NORDETTE-28	ethinyl estradiol; levonorgestrel	TABLET;ORAL-28	018782-001	Jul 21, 1982
Wyeth Pharms Inc	TRIPHASIL-28	ethinyl estradiol; levonorgestrel	TABLET;ORAL-28	019190-001	Nov 1, 1984
Wyeth Pharms	TRIPHASIL-21	ethinyl estradiol; levonorgestrel	TABLET;ORAL-21	019192-001	Nov 1, 1984
Agile	TWIRLA	ethinyl estradiol; levonorgestrel	SYSTEM;TRANSDERMAL	204017-001	Feb 14, 2020
Teva Branded Pharm	SEASONIQUE	ethinyl estradiol; levonorgestrel	TABLET;ORAL	021840-001	May 25, 2006

International Patents for ethinyl estradiol; levonorgestrel

Country	Patent Number	Title	Estimated Expiration
Canada	2524474	METHODES DE TRAITEMENT HORMONAL FAISANT APPEL A DES SCHEMAS CONTRACEPTIFS A CYCLE PROLONGE (METHODS OF HORMONAL TREATMENT UTILIZING EXTENDED CYCLE CONTRACEPTIVE REGIMENS)
Japan	2006525358
European Patent Office	2167002	DISPOSITIF D'ADMINISTRATION DERMIQUE AVEC UN JOINT IN SITU (DERMAL DELIVERY DEVICE WITH IN SITU SEAL)
Japan	2007534622
Argentina	051931
European Patent Office	2392333	Procédé de traitement hormonal utilisant des régimes de cycle étendu à dose croissante (Methods of hormonal treatment utilizing ascending-dose extended cycle regimens)

Supplementary Protection Certificates for ethinyl estradiol; levonorgestrel

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1214076	SZ 49/2008	Austria		PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON
1453521	15C0050	France		PRODUCT NAME: ETHINYLESTRADIOL ET MELANGE DE LEVONORGESTREL ET ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: NL 42237 20150320; FIRST REGISTRATION: SK - 17/0017/15-S 20150129
1453521	122015000093	Germany		PRODUCT NAME: LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 87675.00.00 20150720; FIRST REGISTRATION: SLOWAKEI 17/0017/15-S 20150129
0136011	2000C/027	Belgium		PRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124
1453521	CA 2016 00016	Denmark		PRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211
1214076	C01214076/01	Switzerland		PRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008

Ethinyl Estradiol / Levonorgestrel: Market Dynamics and Financial Trajectory

Last updated: April 25, 2026

What is the product set and what drives pricing power?

Ethinyl estradiol (EE) and levonorgestrel (LNG) are the core active ingredients in widely used combined oral contraceptives (COCs). Commercial products are typically fixed-dose tablets containing EE (commonly 20 mcg or 30 mcg) plus LNG (commonly 100 mcg) or equivalent established dose regimens. The market behaves like a mature, highly substitutable generic and branded-generic ecosystem, with pricing driven by payer formularies, gross-to-net pressure, and unit-volume stability rather than patent leverage.

Key market characteristics

• Substitutability is high: Same therapeutic category (COCs) and overlapping dose strengths create fast switching within formularies.
• Competition is mostly generic-led: Where patent protection has expired for individual dosage forms, price competition dominates.
• Brand differentiation is limited: Product-level differentiation tends to concentrate in dosing frequency, pill appearance/packaging, and patient convenience, with clinical equivalence governed by bioequivalence frameworks.
• Gross-to-net compression is structural: Contracting, rebates, and pharmacy benefit manager (PBM) mechanics reduce realized prices versus list.

Drug and regulatory anchors

• EE and LNG are long-established actives with broad US and EU commercial history, with product access generally stabilized through generics and authorized brands.
• FDA’s drug product framework applies through NDAs/ANDAs and bioequivalence requirements for generics, keeping entry friction lower than for novel drug classes (generic manufacturing + BE package). (FDA: ANDA / Bioequivalence programs) [1]

How does demand behave across the cycle?

The EE/LNG demand cycle is anchored to contraceptive utilization and persistence. Unlike acute-care markets, COCs show steadier volume trends but can still move with:

• Formulary inclusion and step edits (switching between preferred generics or tiers).
• Safety and labeling dynamics (signals can shift preference within estrogen-progestin combinations).
• Supply disruptions (can temporarily tighten availability and lift realized pricing).

Utilization and persistence mechanics

• Unit volume tracks population-level contraception rates and switching within classes.
• Persistence matters because COCs are consumed continuously; discontinuation reduces lifetime units per user.
• Retail and mail channels influence realized pricing via pharmacy contracting.

What are the key competitive forces?

The market’s competitive pressure is not dominated by R&D differentiation; it is dominated by access and cost.

Competition map (practical)

• Generic manufacturers compete on cost-to-serve, contract pricing, and packaging.
• Branded-generic incumbents can retain share via pharmacy familiarity, established contracts, and sometimes less direct price pressure in certain channels.
• Therapeutic class competition spans other combined products and (in some payer designs) progestin-only options, though formularies often keep COCs as the first-line category.

Why price declines are persistent

• Short-to-medium supply of generics plus routine PBM switching pulls realized net price down.
• Entry of additional ANDA labels expands effective supply even when total class demand is stable.
• Promotions matter less than tiering because COCs are repeat-purchase items.

What is the financial trajectory you should expect?

For EE/LNG, the financial trajectory typically follows a genericization pattern:

1. Early branded growth (share formation and brand lift)
2. Patent cliff / generic entry (rapid erosion in realized price)
3. Stabilization via contracts (net price plateaus at a low band while volume holds)
4. Ongoing share shifts based on formulary position and supply reliability

Given the historical depth of the actives, the market is generally in the late-cycle stage, where most upside is access-driven (preferred positioning, contracts, channel mix) rather than product innovation.

Real-world implications for revenue quality

• Revenue growth is volume-driven and constrained by contraceptive utilization and persistence.
• Margin profile tightens as net price falls; manufacturing scale and logistics become decisive.
• Cash conversion is typically strong given mature supply chains and low R&D intensity versus specialty drugs, but working capital can increase around inventory swings during supply constraints.

How do payer and channel dynamics shape revenue?

Revenue outcomes depend on where the product is “preferred” and how that preference is enforced.

Payer mechanics that move net sales

• Formulary tiering: Preferred placement can increase share even when competing products are clinically similar.
• Quantity limits and step therapy: Can push switches within COCs rather than across classes.
• PBM rebate structures: Change realized pricing rapidly as contracts renew.
• State and plan formulary changes: Can trigger short-run demand shifts.

Channel splits

• Retail pharmacies often drive share through stocking and pharmacy counter conversion.
• Mail-order can benefit preferred formulary positioning, especially where the PBM consolidates supply for maintenance medications.
• 340B and institutional channels can alter net pricing and mix, depending on plan structure, inventory management, and rebate eligibility.

How do safety and labeling issues affect market behavior?

EE/LNG market share can shift when safety narratives influence patient and prescriber behavior, especially around estrogen-associated risk perceptions. Even when risk is known and managed, marketing and switching often respond to the perception of relative risk within the class.

What tends to matter

• Updates to labeling language or safety communications (for example, risk framing around thromboembolism).
• Comparative positioning within COC class products based on dose strength.
• Prescriber habits and patient experience with side effects.

What role do dosing variants and lifecycle events play?

EE/LNG products frequently exist in multiple strengths and regimen patterns, commonly including 20 mcg and 30 mcg EE with LNG at common fixed doses. Competitive dynamics often turn on:

• Dose preference: Some prescribers choose a specific EE strength for tolerability.
• Generic interchangeability: Even when dose is the same, pack design and brand familiarity affect repeat purchase decisions.
• Lifecycle maintenance: Product-specific line extensions can protect market presence even after core active patents expire.

Patent and exclusivity landscape: what does it imply for investment returns?

For EE/LNG, most core exclusivity has largely passed for the actives themselves, so near-term returns are driven less by molecule-level patent cliffs and more by:

• Formulation/device patents where present
• Regimen-specific or manufacturing/process patents (if any)
• Regulatory exclusivity for specific ANDAs/NDA supplements (where applicable)

On the US side, generic entry and data exclusivity around specific reference products follow FDA frameworks for ANDAs and exclusivity types, with bioequivalence being the principal regulatory pathway for generic approvals. [1]

What does “financial trajectory” look like at the company level?

Investors typically evaluate EE/LNG as a volume and contract-driven portfolio rather than a high-growth pipeline asset. The trajectory across incumbent and generic entrants usually splits into two profiles:

1) Incumbent brand (or brand-generic) profile

• Revenue: Declines post-genericization, then stabilizes
• Net margin: Compresses due to PBM/rebate pressure
• Strategic focus: Defend formularies, manage supply, and retain share via contract renewal

2) Generic manufacturer profile

• Revenue: More elastic with contract wins and pharmacy tiering
• Net margin: Tightens with increased competition, but can improve when supply constraints exist
• Strategic focus: Win contracts, maintain manufacturing yield, and reduce unit costs

How do manufacturing and supply conditions impact quarterly performance?

COCs can show periodic quarter-to-quarter volatility driven by:

• Batch yields and quality remediation
• Supply chain lead times
• Third-party component constraints
• Regulatory enforcement events impacting certain lots

When supply tightens, realized pricing can temporarily improve even in generic markets, but sustainability depends on how quickly additional supply restores availability.

What are the practical metrics to track for trajectory confirmation?

Business teams typically track:

• Net sales and gross-to-net ratio for each dosage strength and label
• Formulary share in key plan formularies (top PBMs)
• Channel mix (retail vs mail)
• Inventory turns and fill rate as operational quality proxies
• Contract pricing outcomes at renewal

These are the levers that map to a predictable late-cycle market pattern.

What does the regulatory environment imply for future pricing?

EE/LNG sits inside a mature regulatory category where generics can enter through ANDA pathways using bioequivalence and established manufacturing controls. This reduces barriers to new supply and reinforces competitive pricing behavior.

FDA’s generic approval pathway and bioequivalence system are central to how the market sustains generic competition. [1]

Key Takeaways

• EE/LNG is a late-cycle, high-substitutability COC market where pricing is governed by PBM contracts and gross-to-net pressure rather than molecule-level differentiation.
• Demand is steady but not growth-driven: revenue trajectory tracks contraceptive utilization and persistence, with share shifts driven by formulary tiering and contracting.
• Financial outcomes depend on access and operations: contract wins, supply reliability, and unit manufacturing economics drive net sales and margin stability.
• Investment upside is mainly defensive or contract-based: defending preferred positioning and maintaining low-cost supply tends to outperform pipeline-like expectations.

---

FAQs

1) Is EE/LNG growth more dependent on new launches or contract wins?

Contract wins and formulary positioning usually dominate, because EE/LNG products are highly substitutable and pricing power is limited after genericization.

2) Do different EE strengths (for example, 20 mcg vs 30 mcg) materially change market outcomes?

Yes at the margins: prescriber and patient preference within COCs can shift share and affects how each product is placed on formularies, but the category remains interchangeable for many payers.

3) What causes the biggest quarter-to-quarter moves for EE/LNG?

Supply availability, contract renewals, and pharmacy benefit manager tier changes typically drive the largest changes in realized net sales.

4) How should margins be modeled in this market?

Margins typically compress as competition expands and gross-to-net increases; sustaining profitability relies on scale, yield, and negotiating leverage in contracts.

5) What regulatory pathway governs most competitive entries?

In the US, generic competition is commonly enabled through the ANDA pathway with bioequivalence requirements, producing fast follow-on supply in mature dosage forms.

---

References

[1] U.S. Food and Drug Administration. (n.d.). ANDA (Abbreviated New Drug Application) and Bioequivalence. FDA. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda